Mammary Cell News Volume 7.28 | Jul 23 2015

DOT1L Cooperates with the C-Myc-p300 Complex to Epigenetically Derepress CDH1 Transcription Factors in Breast Cancer Progression
The authors identified that DOT1L cooperates with c-Myc and p300 acetyltransferase to epigenetically activate epithelial–mesenchymal transition regulators in breast cancer progression. [Nat Commun] Full Article

KLF5 Promotes Breast Cancer Proliferation, Migration and Invasion in Part by Upregulating the Transcription of TNFAIP2
Investigators demonstrated that TNFAIP2, a tumor necrosis factor-α-induced gene, is a direct Kruppel-like factor 5 (KLF5) target gene. The expression of TNFAIP2 is highly correlated with the expression of KLF5 in breast cancers. [Oncogene] Abstract

LMTK3 Represses Tumor Suppressor-Like Genes through Chromatin Remodeling in Breast Cancer
Researchers identified KRAB-associated protein 1 (KAP1) as a binding partner of LMTK3. The LMTK3/KAP1 interaction is stabilized by PP1α, which suppresses KAP1 phosphorylation specifically at LMTK3-associated chromatin regions, inducing chromatin condensation and resulting in transcriptional repression of LMTK3-bound tumor suppressor-like genes. [Cell Rep] Full Article | Graphical Abstract | Press Release

Blockade of Wnt/β-Catenin Signaling Suppresses Breast Cancer Metastasis by Inhibiting CSC-Like Phenotype
Researchers investigated the effects of inhibiting Wnt/β-catenin signaling on cancer cell migratory potential by examining the expression of cancer stem cell (CSC)-related genes, and they examined how this pathway links metastatic potential with tumor formation in vitro and in vivo. [Sci Rep] Full Article

Rap2B Promotes Proliferation, Migration, and Invasion of Human Breast Cancer through Calcium-Related ERK1/2 Signaling Pathway
Rap2B knockdown inhibits cell proliferation, migration, and invasion abilities via calcium related-ERK1/2 signaling. In addition, overexpression of Rap2B promotes cell proliferation, migration and invasion abilities, which could be neutralized by BAPTM/AM and U0126. [Sci Rep] Full Article

miR-205-5p-Mediated Downregulation of ErbB/HER Receptors in Breast Cancer Stem Cells Results in Targeted Therapy Resistance
Researchers report that miR-205-5p is highly expressed in breast cancer stem cells and represses directly ERBB2 and indirectly EGFR leading to resistance to targeted therapy. [Cell Death Dis] Full Article

Mimicking Postmenopausal Steroid Metabolism in Breast Cancer Cell Culture: Differences in Response to DHEA or Other Steroids as Hormone Sources.
Investigators presented a comparative study of steroid-converting enzymes with the provision of dehydroepiandrosterone (DHEA) and the direct substrates, estrone or dihydrotestosterone, or additional steroids as hormone sources, in breast cancer cells. [J Steroid Biochem Mol Biol] Abstract

Regulation of Stem Cells-Related Signaling Pathways in Response to Doxorubicin Treatment in Hs578T Triple-Negative Breast Cancer Cells
The authors investigated the cellular and molecular signaling of two claudin-low triple-negative breast cancer cells to doxorubicin and docetaxel treatment. While the treatment reduced the proliferation, aggregation and mammosphere forming ability of stem-like cells derived from Hs578T cell line, stem-like cells derived from MDA-MB-231 cells were not significantly affected. [Mol Cell Biochem] Abstract

Local Variations of HER2 Dimerization in Breast Cancer Cells Discovered by Correlative Fluorescence and Liquid Electron Microscopy
The authors studied the intra- and intercellular variation of HER2 at the single-molecule level in intact SKBR3 breast cancer cells. [Science Advances] Abstract | Press Release

CLINICAL RESEARCH

A Phase I Trial of Combined Ridaforolimus and MK-2206 in Patients with Advanced Malignancies
Scientists assessed dose-limiting toxicities and maximum-tolerated dose for the combination of oral ridaforolimus plus oral MK-2206 in patients with advanced solid tumors. Efficacy was evaluated in patients with biomarker-identified estrogen receptor-positive breast cancer or castration-resistant prostate cancer with PI3K pathway addiction. [Clin Cancer Res] Abstract

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial
Investigators determined the efficacy and safety of bevacizumab-modified FOLFOX6 regimen in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2/neu)-negative metastic breast cancer. [PLoS One] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Blaze Bioscience Announces Open Enrollment for Phase I Clinical Trial of Tumor Paint BLZ-100 in Patients with Solid Tumor Cancers
Blaze Bioscience, a biotechnology company focused on guided cancer therapy, announced expansion of its Phase I program into multiple additional tumor types. [Blaze Bioscience] Press Release

Dr. Mothaffar Rimawi Recognized for Outstanding Contributions to Breast Cancer
Dr. Mothaffar Rimawi, medical director of the Lester and Sue Smith Breast Center at Baylor College of Medicine, has been selected to receive the C. Kent Osborne Award for Medical Excellence for his outstanding contributions to breast cancer research, advocacy and patient care. [Baylor College of Medicine] Press Release

From our sponsor: Culturing hematopoietic stem and progenitor cells? Download the technical bulletin.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Senior Product Manager – Breast Cancer (Celgene Corporation)

Postdoctoral Research Fellow (Fred Hutchinson Cancer Research Center)

Research Associate/ Assistant Professor – Breast Cancer (University of Chicago)

Postdoctoral Research Associate – Breast Stem Cell Biology (University of Miami Miller School of Medicine)

Postdoctoral Researcher – Breast Cancer (University of Oxford)

Postdoctoral Fellow – Oncolytic Viruses (Mayo Clinic – Rochester)

Postdoctoral Positions – Breast Cancer (University of Texas MD Anderson Cancer Center)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.